COMPANY

EpicentRx

HQ: La Jolla, CA source · epicentrx.com ↗

Keywords: small molecule Lymphomas Oral Mucositis Small Cell Lung Carcinoma Sarcoma Sarcoma,Soft Tissue Chondrosarcoma Small Cell Carcinoma Non-Small-Cell Lung Carcinoma Neuroendocrine Tumors Ovarian Epithelial Cancer Recurrent Brain Tumor Pediatric Brain Tumor Central Nervous System Neoplasms Protocol Specific Unspecified Childhood Solid Tumor Colorectal Neoplasms Cholangiocarcinoma Glioblastoma Oligodendroglioma Anaplastic Oligodendroglioma Brain Metastases RRx-001

Location: La Jolla, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

16Trials (company is sponsor)

Timeline

Apr 2, 2024 Trial start Phase 2: RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer source ↗
Jan 26, 2023 Trial start Phase 1: RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors source ↗
Aug 1, 2022 Trial start 3: A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer source ↗
Mar 29, 2021 Trial start Phase 2: A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors source ↗
Dec 24, 2018 Trial start Phase 3: RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer source ↗
Jul 12, 2018 Trial start Phase 2: Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers source ↗
Feb 14, 2017 Trial start Phase 1: RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas source ↗
Aug 30, 2016 Trial start Phase 1: RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) source ↗
Jul 21, 2015 Trial start I: A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab source ↗
Jul 16, 2015 Trial start Phase 2: RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy source ↗
2015-06 Trial start Phase 2: RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) source ↗
Feb 6, 2015 Trial start Phase 1: Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases source ↗
2014-05 Trial start 2: A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer source ↗
2014-04 Trial start 1: A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001 source ↗
2011-09 Trial start Phase 1: Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects source ↗

Upcoming milestones

Dec 1, 2026 (ESTIMATED) · Phase 2 · A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors · NCT04673942
Jul 1, 2027 (ESTIMATED) · Phase 2 · RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer · NCT05966194

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 16

Record	Title	Phase	Status	Start	Primary completion
NCT05966194	RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer	Phase 2	Active, not recruiting	Apr 2, 2024	Jul 1, 2027 (estimated)
NCT04673942	A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors	Phase 2	Active, not recruiting	Mar 29, 2021	Dec 1, 2026 (estimated)
NCT02489903	RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)	Phase 2	Completed	2015-06	Dec 6, 2021 (actual)
NCT03515538	Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers	Phase 2	Completed	Jul 12, 2018	Oct 22, 2019 (actual)
NCT01359982	Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects	Phase 1	Completed	2011-09	2015-02 (actual)
NCT04525014	RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors	Phase 1	Terminated	Jan 26, 2023	Jul 29, 2024 (actual)
NCT05566041	A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer	3	Active, not recruiting	Aug 1, 2022	Dec 31, 2025 (estimated)
NCT02096354	A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer	2	Completed	2014-05	Apr 13, 2018 (actual)
NCT02452970	RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy	Phase 2	Terminated	Jul 16, 2015	May 10, 2016 (actual)
NCT03699956	RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer	Phase 3	Terminated	Dec 24, 2018	Aug 11, 2022 (actual)
NCT02801097	RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)	Phase 1	Terminated	Aug 30, 2016	Nov 22, 2018 (actual)
NCT02871843	RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas	Phase 1	Completed	Feb 14, 2017	Oct 11, 2019 (actual)
NCT02215512	Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases	Phase 1	Completed	Feb 6, 2015	Nov 28, 2016 (actual)
NCT02518958	A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab	I	Completed	Jul 21, 2015	May 17, 2016 (actual)
NCT03529539	Expanded Access for PSV Personalized Oncolytic Viruses	Not listed	No longer available	Not listed	Not listed
NCT02096341	A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001	1	Terminated	2014-04	2016-01 (actual)